PMC:7104244 / 2566-3455 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"35","span":{"begin":43,"end":53},"obj":"Species"},{"id":"36","span":{"begin":174,"end":184},"obj":"Species"},{"id":"37","span":{"begin":476,"end":484},"obj":"Species"},{"id":"41","span":{"begin":442,"end":467},"obj":"Disease"},{"id":"42","span":{"begin":497,"end":505},"obj":"Disease"}],"attributes":[{"id":"A35","pred":"tao:has_database_id","subj":"35","obj":"Tax:2697049"},{"id":"A36","pred":"tao:has_database_id","subj":"36","obj":"Tax:2697049"},{"id":"A37","pred":"tao:has_database_id","subj":"37","obj":"Tax:9606"},{"id":"A41","pred":"tao:has_database_id","subj":"41","obj":"MESH:D012817"},{"id":"A42","pred":"tao:has_database_id","subj":"42","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"gently needed, as the risk of transmitting SARS-CoV-2 by faecal microbiota transplantation might be higher than that in other tissue transplants. Evidence has shown that the SARS-CoV-2 can be found in faeces, and that stool samples can remain positive for the virus even when it is no longer detectable in the respiratory tract, suggesting the possibility of a faecal–oral route of transmission.9 This concept is supported by the presence of gastrointestinal symptoms in some patients affected by COVID-19.10 Another relevant issue is that faecal microbiota transplantation is not classified in the same way worldwide, as some countries regulate these transplants as a drug (eg, the USA, the UK, and France), some as a tissue (eg, Italy), and others do not provide specific regulation (eg, Australia).8 This discrepancy results in a confusing scenario, in which some countries will apply r"}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T66","span":{"begin":43,"end":53},"obj":"SP_7"},{"id":"T65","span":{"begin":126,"end":132},"obj":"UBERON:0000479"},{"id":"T64","span":{"begin":174,"end":184},"obj":"SP_7"},{"id":"T63","span":{"begin":201,"end":207},"obj":"UBERON:0001988"},{"id":"T62","span":{"begin":218,"end":223},"obj":"UBERON:0001988"},{"id":"T61","span":{"begin":260,"end":265},"obj":"NCBITaxon:10239"},{"id":"T60","span":{"begin":310,"end":327},"obj":"UBERON:0000065"},{"id":"T59","span":{"begin":368,"end":372},"obj":"UBERON:0000165"},{"id":"T58","span":{"begin":442,"end":458},"obj":"UBERON:0001555"},{"id":"T57","span":{"begin":497,"end":505},"obj":"SP_7"},{"id":"T56","span":{"begin":637,"end":645},"obj":"GO:0065007"},{"id":"T55","span":{"begin":669,"end":673},"obj":"CHEBI:23888;CHEBI:23888"},{"id":"T54","span":{"begin":719,"end":725},"obj":"UBERON:0000479"},{"id":"T53","span":{"begin":774,"end":784},"obj":"GO:0065007"}],"text":"gently needed, as the risk of transmitting SARS-CoV-2 by faecal microbiota transplantation might be higher than that in other tissue transplants. Evidence has shown that the SARS-CoV-2 can be found in faeces, and that stool samples can remain positive for the virus even when it is no longer detectable in the respiratory tract, suggesting the possibility of a faecal–oral route of transmission.9 This concept is supported by the presence of gastrointestinal symptoms in some patients affected by COVID-19.10 Another relevant issue is that faecal microbiota transplantation is not classified in the same way worldwide, as some countries regulate these transplants as a drug (eg, the USA, the UK, and France), some as a tissue (eg, Italy), and others do not provide specific regulation (eg, Australia).8 This discrepancy results in a confusing scenario, in which some countries will apply r"}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T16","span":{"begin":126,"end":132},"obj":"Body_part"},{"id":"T17","span":{"begin":201,"end":207},"obj":"Body_part"},{"id":"T18","span":{"begin":218,"end":223},"obj":"Body_part"},{"id":"T19","span":{"begin":310,"end":327},"obj":"Body_part"},{"id":"T20","span":{"begin":719,"end":725},"obj":"Body_part"}],"attributes":[{"id":"A16","pred":"fma_id","subj":"T16","obj":"http://purl.org/sig/ont/fma/fma9637"},{"id":"A17","pred":"fma_id","subj":"T17","obj":"http://purl.org/sig/ont/fma/fma64183"},{"id":"A18","pred":"fma_id","subj":"T18","obj":"http://purl.org/sig/ont/fma/fma64183"},{"id":"A19","pred":"fma_id","subj":"T19","obj":"http://purl.org/sig/ont/fma/fma265130"},{"id":"A20","pred":"fma_id","subj":"T20","obj":"http://purl.org/sig/ont/fma/fma9637"}],"text":"gently needed, as the risk of transmitting SARS-CoV-2 by faecal microbiota transplantation might be higher than that in other tissue transplants. Evidence has shown that the SARS-CoV-2 can be found in faeces, and that stool samples can remain positive for the virus even when it is no longer detectable in the respiratory tract, suggesting the possibility of a faecal–oral route of transmission.9 This concept is supported by the presence of gastrointestinal symptoms in some patients affected by COVID-19.10 Another relevant issue is that faecal microbiota transplantation is not classified in the same way worldwide, as some countries regulate these transplants as a drug (eg, the USA, the UK, and France), some as a tissue (eg, Italy), and others do not provide specific regulation (eg, Australia).8 This discrepancy results in a confusing scenario, in which some countries will apply r"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T10","span":{"begin":126,"end":132},"obj":"Body_part"},{"id":"T11","span":{"begin":201,"end":207},"obj":"Body_part"},{"id":"T12","span":{"begin":218,"end":223},"obj":"Body_part"},{"id":"T13","span":{"begin":310,"end":327},"obj":"Body_part"},{"id":"T14","span":{"begin":719,"end":725},"obj":"Body_part"}],"attributes":[{"id":"A10","pred":"uberon_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/UBERON_0000479"},{"id":"A11","pred":"uberon_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/UBERON_0001988"},{"id":"A12","pred":"uberon_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/UBERON_0001988"},{"id":"A13","pred":"uberon_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/UBERON_0000065"},{"id":"A14","pred":"uberon_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/UBERON_0000479"}],"text":"gently needed, as the risk of transmitting SARS-CoV-2 by faecal microbiota transplantation might be higher than that in other tissue transplants. Evidence has shown that the SARS-CoV-2 can be found in faeces, and that stool samples can remain positive for the virus even when it is no longer detectable in the respiratory tract, suggesting the possibility of a faecal–oral route of transmission.9 This concept is supported by the presence of gastrointestinal symptoms in some patients affected by COVID-19.10 Another relevant issue is that faecal microbiota transplantation is not classified in the same way worldwide, as some countries regulate these transplants as a drug (eg, the USA, the UK, and France), some as a tissue (eg, Italy), and others do not provide specific regulation (eg, Australia).8 This discrepancy results in a confusing scenario, in which some countries will apply r"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T13","span":{"begin":43,"end":51},"obj":"Disease"},{"id":"T14","span":{"begin":174,"end":182},"obj":"Disease"}],"attributes":[{"id":"A13","pred":"mondo_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A14","pred":"mondo_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"gently needed, as the risk of transmitting SARS-CoV-2 by faecal microbiota transplantation might be higher than that in other tissue transplants. Evidence has shown that the SARS-CoV-2 can be found in faeces, and that stool samples can remain positive for the virus even when it is no longer detectable in the respiratory tract, suggesting the possibility of a faecal–oral route of transmission.9 This concept is supported by the presence of gastrointestinal symptoms in some patients affected by COVID-19.10 Another relevant issue is that faecal microbiota transplantation is not classified in the same way worldwide, as some countries regulate these transplants as a drug (eg, the USA, the UK, and France), some as a tissue (eg, Italy), and others do not provide specific regulation (eg, Australia).8 This discrepancy results in a confusing scenario, in which some countries will apply r"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T25","span":{"begin":155,"end":158},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T26","span":{"begin":260,"end":265},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T27","span":{"begin":359,"end":360},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T28","span":{"begin":667,"end":668},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T29","span":{"begin":717,"end":718},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T30","span":{"begin":831,"end":832},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"gently needed, as the risk of transmitting SARS-CoV-2 by faecal microbiota transplantation might be higher than that in other tissue transplants. Evidence has shown that the SARS-CoV-2 can be found in faeces, and that stool samples can remain positive for the virus even when it is no longer detectable in the respiratory tract, suggesting the possibility of a faecal–oral route of transmission.9 This concept is supported by the presence of gastrointestinal symptoms in some patients affected by COVID-19.10 Another relevant issue is that faecal microbiota transplantation is not classified in the same way worldwide, as some countries regulate these transplants as a drug (eg, the USA, the UK, and France), some as a tissue (eg, Italy), and others do not provide specific regulation (eg, Australia).8 This discrepancy results in a confusing scenario, in which some countries will apply r"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T5","span":{"begin":669,"end":673},"obj":"Chemical"}],"attributes":[{"id":"A5","pred":"chebi_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"}],"text":"gently needed, as the risk of transmitting SARS-CoV-2 by faecal microbiota transplantation might be higher than that in other tissue transplants. Evidence has shown that the SARS-CoV-2 can be found in faeces, and that stool samples can remain positive for the virus even when it is no longer detectable in the respiratory tract, suggesting the possibility of a faecal–oral route of transmission.9 This concept is supported by the presence of gastrointestinal symptoms in some patients affected by COVID-19.10 Another relevant issue is that faecal microbiota transplantation is not classified in the same way worldwide, as some countries regulate these transplants as a drug (eg, the USA, the UK, and France), some as a tissue (eg, Italy), and others do not provide specific regulation (eg, Australia).8 This discrepancy results in a confusing scenario, in which some countries will apply r"}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T1","span":{"begin":774,"end":784},"obj":"http://purl.obolibrary.org/obo/GO_0065007"}],"text":"gently needed, as the risk of transmitting SARS-CoV-2 by faecal microbiota transplantation might be higher than that in other tissue transplants. Evidence has shown that the SARS-CoV-2 can be found in faeces, and that stool samples can remain positive for the virus even when it is no longer detectable in the respiratory tract, suggesting the possibility of a faecal–oral route of transmission.9 This concept is supported by the presence of gastrointestinal symptoms in some patients affected by COVID-19.10 Another relevant issue is that faecal microbiota transplantation is not classified in the same way worldwide, as some countries regulate these transplants as a drug (eg, the USA, the UK, and France), some as a tissue (eg, Italy), and others do not provide specific regulation (eg, Australia).8 This discrepancy results in a confusing scenario, in which some countries will apply r"}